Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma
Zevalin may be an effective therapy for newly diagnosed marginal zone lymphoma (MZL).
Marginal Zone Lymphoma
DRUG: Rituximab|DRUG: Ibritumomab Tiuxetan
Overall Rate of Response (ORR) in Participants Receiving Protocol Therapy., The overall response rate (ORR) including complete response (CR), complete response unconfirmed (CRu), and partial response (PR) in participants receiving protocol therapy., 12 weeks post-therapy
Rate of Progression-Free Survival, The time from the start of protocol therapy until the first documented or confirmed disease progression, or death related to study disease, whichever is earlier., End of study.|5-Year Rate of Progression-Free Survival (5-Year PFS), Percentage of participants still alive without disease progression five years after the date of protocol therapy initiation., 5 Years|Overall Survival (OS) Rate, The time from the date of initiation of study treatment until date of death from any cause for all participants., End of Study|5 Year Rate of Overall Survival (5-Year OS), Percentage of participants still alive five years after the date of protocol therapy initiation., 5 Years|Number of Participants With Unacceptable Toxicity., Number of participants with treatment-related (possible, probable, or definite) grade 3 or higher non-hematologic adverse events., Up to 12 weeks post-therapy
This phase II study will assess the clinical response rate to Ibritumomab Tiuxetan in patients with untreated nodal, splenic and non-gastric extranodal MZL as well as in antibiotic resistant patients with mucosa-associated lymphoid tissue (MALT) gastric lymphoma.